The conversation discusses using TH16, a topical melatonin with resveratrol, and stemoxydine for hair maintenance, avoiding finasteride and minoxidil due to side effects. The user is considering a low-dose topical finasteride despite sensitivity.
The conversation discusses a hair loss and scalp care routine involving ciclopirox shampoo, benzoyl peroxide, clindamycin gel, clobetasol propionate, and calcipotriol to manage seborrheic dermatitis, folliculitis, and inflammation. It also touches on the role of diet and other treatments like oral minoxidil and pioglitazone for scalp health.
A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.
The user experienced hair regrowth after four months of using finasteride, dutasteride, and oral minoxidil. They noted increased oiliness in their hair after starting the treatment.
The user is using oral minoxidil and finasteride for hair loss and plans to add topical minoxidil and a dermaroller. They also use ketoconazole shampoo to support hair regrowth.
The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.
Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.
The user experienced significant hair improvement after 4 months of using 1.25mg finasteride daily and 5% Minoxidil foam. They reported no side effects and no noticeable shedding phase.
The user is discussing their hair regrowth progress after using 1mg finasteride, minoxidil, and tretinoin for over two months. They are comparing photos from different stages of their treatment to assess improvement.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
A user has been using finasteride and minoxidil for 4-5 months, along with D3 and Biotin supplements, and is seeking feedback on hair regrowth progress. Responses are mixed, with some noticing slight improvements in density and thickness, while others see no change.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
The conversation is about the effectiveness of low-level laser therapy (LLLT) caps for hair regrowth. One user suggests saving money, implying LLLT caps may not be beneficial.
Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.
Using tretinoin with minoxidil can cause burning and flaky skin due to alcohol in minoxidil and tretinoin's effects. Solutions include using minoxidil foam, starting with low tretinoin doses, moisturizing, and gradually increasing usage.
The conversation is about dealing with hair loss, with the original poster deciding to start using topical finasteride and minoxidil after unsuccessful PRP and Regenera treatments. Others share their experiences with hair loss, treatments, and the importance of finasteride to prevent further hair loss.
A user with diffuse hair loss for a decade tried various treatments, including LLLT Helmet, supplements, topicals, and hair transplants. They found relief from scalp inflammation and itching using a topical solution made from crushed Xeljanz pills mixed with ethyl alcohol.
1% finasteride is considered too high, with most people using 0.1% or 0.3% topically. Combining it with 0.1% tretinoin is aggressive and may cause skin irritation.
Rating treatments for hair loss, with the help of GPT-4, according to efficacy, evidence and tolerability; a combination of chemicals from research papers, custom compounds, and some suggestions from other users were included.
The user has been using topical minoxidil 6% and finasteride 0.05% once daily, along with microneedling, vitamins, and nizoral shampoo. They recently increased the topical treatments to twice daily for faster results, experiencing only initial shedding.
The conversation is about using tretinoin with a topical finasteride/minoxidil spray for hair loss. The user seeks information on combining tretinoin with their current treatment.
Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.
The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.
User "mo_movic" shared 4-month progress using finasteride, minoxidil, ketoconazole, and dermaroller for hair loss. Others congratulated and discussed their own experiences, with "mo_movic" reducing finasteride dose and using ketoconazole twice a week.
RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.
The user reported progress in hair growth after 4 months using 0.5 mg finasteride and 2.5 mg minoxidil daily, and is considering adding RU58841 to block DHT on the scalp. They experienced side effects like reduced libido and mild erectile dysfunction, and take supplements like zinc, iron, fish oil, vitamin D, magnesium, and vitamin E.